Nonspecific immunoglobulin replacement in lung transplantation recipients with hypogammaglobulinemia: a cohort study taking into account propensity score and immortal time bias.

Transplantation

1 Clinique Universitaire de Pneumologie, Pôle Thorax et Vaisseaux, CHU Grenoble, Grenoble, France. 2 INSERM CIC3, Centre d'Investigation Clinique, CHU Grenoble, Grenoble, France. 3 Université Grenoble Alpes, UFR de Pharmacie, Grenoble, France. 4 Pharmacie hospitalière, CHU Grenoble, Grenoble, France. 5 CNRS, TIMC-IMAG 5525, Grenoble, France. 6 Clinique Universitaire des Maladies infectieuses, CHU Grenoble, Grenoble, France. 7 Laboratoire d'histocompatibilité, Etablissement Français du sang Rhône-Alpes, Lyon, France. 8 Univ. Grenoble Alpes, LBFA, Grenoble, France. 9 INSERM, LBFA, F-38000 Grenoble, France. 10 CRNH Rhône-Alpes, Pierre-Bénite, France. 11 European Institute of Systems Biology and Medicine, Lyon, France.

Published: February 2015

Background: After lung transplantation (LT), immunoglobulin (Ig) G plasma concentrations<6 g/L are common and correlate with an increased risk of chronic lung allograft dysfunction (CLAD) and a poorer survival.

Methods: We conducted an open substitution intervention with nonspecific intravenous Ig (IVIg), in all patients with IgG plasma less than 6 g/L post-LT in 54 of 84 consecutive recipients since 1998 who survived more than 3 months. Pre-LT and post-LT events were retrospectively analyzed.

Results: Both substituted and nonsubstituted groups demonstrated similar donor or recipient characteristics and events over a median follow-up of 2.8 years (Q1-Q3, 1.4-5.7], except for initial diagnosis with more chronic obstructive pulmonary disease patients and less cases of pulmonary arterial hypertension in NS group. Intravenous Ig substitution started 3.5 months (0.5-9.4) after transplantation and lasted 4.5 months after (1.0-17.7), mean cumulative dose was 52.8±47.7 g. In multivariate Cox regression model, hypogammaglobulinemic patients who were substituted with IVIg had actually a 5-year survival (hazard ratio, 0.63; 95% confidence interval, 0.26-1.49; P=0.29) and CLAD-free 5-year survival (hazard ratio, 0.51; 95% confidence interval, 0.15-1.67; P=0.27) really close to nonhypogammaglobulinemic and nonsubstituted patients. Complementary analysis using propensity score and time-dependent analysis showed that survival and CLAD-free survival were not different in both groups.

Conclusion: Intravenous Ig post-LT achieved similar survival and CLAD-free survival in recipients with hypogammaglobulinemia as compared to those with normal IgG plasmatic rate. A randomized control trial is required to confirm benefic effects of IVIg and disentangle mechanisms, including protection from infections, acute cellular and humoral rejections in patients with hypogammaglobulinemia after LT.

Download full-text PDF

Source
http://dx.doi.org/10.1097/TP.0000000000000339DOI Listing

Publication Analysis

Top Keywords

lung transplantation
8
nonspecific immunoglobulin
4
immunoglobulin replacement
4
replacement lung
4
transplantation recipients
4
recipients hypogammaglobulinemia
4
hypogammaglobulinemia cohort
4
cohort study
4
study account
4
account propensity
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!